Literature DB >> 12174339

Signal transduction pathways: the molecular basis for targeted therapies.

Stephen P Ethier1.   

Abstract

The elucidation of the signal transduction pathways that regulate cell growth and differentiation has led to a number of exciting opportunities for novel cancer therapies. It is now well known that growth factors and cell matrix molecules activate cognate growth factor receptors and integrins, respectively, to initiate a complex signaling cascade that ultimately targets the nucleus, cell surface, and mitochondria. Signaling to these target molecules results in the regulation of gene transcription, cell adhesion and motility, and cell survival, all of which are integral parts of cellular growth control mechanisms. As a result of increased understanding of cell growth regulation mechanisms, a number of novel therapeutic agents have been developed and tested in preclinical models and, to some extent, in clinical trials. Based on our current understanding of growth regulation in normal and cancer cells, one would predict that these new agents could influence proliferation and survival of cancer cells, as well as their response to traditional cytotoxic therapies. In this overview, the mechanistic basis for the use of signal transduction-targeted novel therapeutics is presented, along with predictions regarding how they may interact with ionizing radiation in different subgroups of patients. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174339     DOI: 10.1053/srao.2002.34863

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  7 in total

1.  Silver(I) metallodrugs of thiosemicarbazones and naproxen: biocompatibility, in vitro anti-proliferative activity and in silico interaction studies with EGFR, VEGFR2 and LOX receptors.

Authors:  Sundaram Bharathi; Dharmasivam Mahendiran; Raju Senthil Kumar; Hyo Jeong Choi; Mani Gajendiran; Kyobum Kim; Aziz Kalilur Rahiman
Journal:  Toxicol Res (Camb)       Date:  2020-03-11       Impact factor: 3.524

Review 2.  [Preclinical models in head and neck tumors : Evaluation of cellular and molecular resistance mechanisms in the tumor microenvironment].

Authors:  A Affolter; J Hess
Journal:  HNO       Date:  2016-12       Impact factor: 1.284

3.  EGFR signaling downstream of EGF regulates migration, invasion, and MMP secretion of immortalized cells derived from human ameloblastoma.

Authors:  Marina Rolo Pinheiro da Rosa; Aline Semblano Carreira Falcão; Hellen Thais Fuzii; Maria Sueli da Silva Kataoka; André L R Ribeiro; Enrique Boccardo; Adriane Sousa de Siqueira; Ruy G Jaeger; João de Jesus Viana Pinheiro; Sérgio de Melo Alves Júnior
Journal:  Tumour Biol       Date:  2014-08-07

4.  Anti-EGFR antibody conjugated organic-inorganic hybrid lipid nanovesicles selectively target tumor cells.

Authors:  Siu Ling Leung; Zhengbao Zha; Celine Cohn; Zhifei Dai; Xiaoyi Wu
Journal:  Colloids Surf B Biointerfaces       Date:  2014-06-11       Impact factor: 5.268

5.  Identification of potent EGFR inhibitors from TCM Database@Taiwan.

Authors:  Shun-Chieh Yang; Su-Sen Chang; Hsin-Yi Chen; Calvin Yu-Chian Chen
Journal:  PLoS Comput Biol       Date:  2011-10-13       Impact factor: 4.475

6.  The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series.

Authors:  Muhammad W Saif; Ewa Kontny; Kostas N Syrigos; Armin Shahrokni
Journal:  J Oncol       Date:  2011-06-13       Impact factor: 4.375

7.  Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.

Authors:  Siyang Feng; Yuanyuan Wang; Kaican Cai; Hua Wu; Gang Xiong; Haofei Wang; Ziliang Zhang
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.